A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair ...

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...

Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, the University of Kiel, and the Leibniz Institute of ...

Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pulmonary angiography, specifically the computed tomographic version, is the gold standard for diagnosing lung embolism.

I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I’m dealing with the effects of it ...

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are ...

in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in ...

People with pulmonary arterial hypertension and their physicians hardly ever agree on the severity of symptoms, a study shows ...

Merck’s Winrevair (sotatercept) for PAH Winrevair was greenlit March 26 for treating adults with pulmonary arterial hypertension (PAH), based on ... the excitement is that Ohtuvayre is a ...